Estimates of young breast cancer survivors at risk for infertility in the U.S

Oncologist

Volumn 19, Issue 8, 2014, Pages 814-822

  Trivers, Katrina F ^a   Fink, Aliza K ^b   Partridge, Ann H ^c,d   Oktay, Kutluk ^e,f   Ginsburg, Elizabeth S ^d   Li, Chunyu ^a   Pollack, Lori A ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b ICF INTERNATIONAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e NEW YORK MEDICAL COLLEGE   (United States)

^f Institute for Fertility Preservation   (United States)

Author keywords

Breast neoplasms; Fertility preservation; Infertility; Pregnancy; Reproductive behavior; Survivors

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVOR; COUNSELING; ETHNICITY; FEMALE; FEMALE INFERTILITY; FERTILITY PRESERVATION; HEALTH HAZARD; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RACE; RISK; RISK FACTOR; UNITED STATES; YOUNG ADULT; BREAST NEOPLASMS; CHEMICALLY INDUCED; COMPLICATION; INFERTILITY, FEMALE; PATHOLOGY; SURVIVOR;

ADOLESCENT; ADULT; BREAST NEOPLASMS; FEMALE; FERTILITY PRESERVATION; HUMANS; INFERTILITY, FEMALE; SURVIVORS; UNITED STATES;

EID: 84905447297     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0016     Document Type: Article

References (47)

1. Soleimani R, Heytens E, Darzynkiewicz Z et al. Mechanisms of chemotherapy-induced human ovarian aging: Double strand DNA breaks and microvascular compromise. Aging (Albany, NY) 2011; 3: 782-793.
2. Ruddy KJ, Partridge AH. The unique reproductive concerns of young women with breast cancer. Adv Exp Med Biol 2012; 732: 77-87.
3. Partridge AH, Gelber S, Peppercorn J et al. Fertility and menopausal outcomes in young breast cancer survivors. Clin Breast Cancer 2008; 8: 65-69.
4. Hulvat MC, Jeruss JS. Fertility preservation options for young women with breast cancer. Curr Opin Obstet Gynecol 2011; 23: 174-182.
5. Rodriguez-Wallberg KA, Oktay K. Fertility preservation in women with breast cancer. Clin Obstet Gynecol 2010; 53: 753-762.
6. Braems G, Denys H, De Wever O et al. Use of tamoxifen before and during pregnancy. The Oncologist2011; 16: 1547-1551.
7. Letourneau JM, Ebbel EE, Katz PP et al. Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer 2012; 118: 1933-1939.
8. Loren AW, Mangu PB, Beck LN et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2500-2510.
9. Oktay K, Sönmezer M. Chemotherapy and amenorrhea: Risks and treatment options. Curr Opin Obstet Gynecol 2008; 20: 408-415.
10. Ganz PA, Land SR, Geyer CE Jr. et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol 2011; 29: 1110-1116.
11. Abusief ME, Missmer SA, Ginsburg ES et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010; 116: 791-798.
12. United States Cancer Statistics (USCS). 1999-2009 incidence and mortality data. Available at http: //www. cdc. gov/cancer/npcr/uscs/download_ data. htm. Accessed December 1, 2013.
13. Surveillance, Epidemiology, and End Results program [SEER*Stat database: Incidence, SEER 9 registration research data, November 2011 submission, vintage 2009 populations (1973-2009)]. Available at http: //seer. cancer. gov/. Accessed December 1, 2013.
14. Previous version: SEER cancer statistics review, 1975-2009 (vintage 2009 populations). Available at http: //seer. cancer. gov/csr/1975_2009_pops09/. Updated August 20, 2012. Accessed December 1, 2013.
15. Practice Committees of American Society for Reproductive Medicine; Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: A guideline. Fertil Steril 2013; 99: 37-43.
16. Jukkala AM, Azuero A, McNees P et al. Selfassessed knowledge of treatment and fertility preservation in young women with breast cancer. Fertil Steril 2010; 94: 2396-2398.
17. Howard-Anderson J, Ganz PA, Bower JE et al. Quality of life, fertility concerns, and behavioral health outcomes in younger breast cancer survivors: A systematic review. J Natl Cancer Inst 2012; 104: 386-405.
18. Partridge AH, Gelber S, Peppercorn J et al. Web-based survey of fertility issues in young women with breast cancer. J Clin Oncol 2004; 22: 4174-4183.
19. Duffy CM, Allen SM, Clark MA. Discussions regarding reproductive health for young women with breast cancer undergoing chemotherapy. J Clin Oncol 2005; 23: 766-773.
20. Thewes B, Meiser B, Taylor A et al. Fertility-and menopause-related information needs of younger women with a diagnosis of early breast cancer. J Clin Oncol 2005; 23: 5155-5165.
21. Letourneau JM, Smith JF, Ebbel EE et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer 2012; 118: 4579-4588.
22. Quinn GP, Vadaparampil ST, Gwede CK et al. Discussion of fertility preservation with newly diagnosed patients: Oncologists' views. J Cancer Surviv 2007; 1: 146-155.
23. Niemasik EE, Letourneau J, Dohan D et al. Patient perceptions of reproductive health counseling at the time of cancer diagnosis: A qualitative study of female California cancer survivors. J Cancer Surviv 2012; 6: 324-332.
24. Quinn GP, Vadaparampil ST, Lee JH et al. Physician referral for fertility preservation in oncology patients: A national study of practice behaviors. J Clin Oncol 2009; 27: 5952-5957.
25. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in cancer patients. Fertil Steril 2005; 83: 1622-1628.
26. Lee S, Ozkavukcu S, Heytens E et al. Value of early referral to fertility preservation in young women with breast cancer. J Clin Oncol 2010; 28: 4683-4686.
27. United States Cancer Statistics (USCS) [1999-2007 incidence and mortality data]. Available at http: //www. cdc. gov/cancer/npcr/uscs/ download_data. htm.
28. Havener L, Hulstrom D. Standards for cancer registries, volume II: Data standards and data dictionary. 10th ed., version 11.1. Springfield, IL: North American Association of Central Cancer Registries, 2006.
29. Wu XC, Lund MJ, Kimmick GG et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol 2012; 30: 142-150.
30. NCCN clinical practice guidelines in oncology (NCCN Guidelines). Breast cancer. Available at http: //www. nccn. org/professionals/physician_gls/ f_guidelines. asp#site.
31. National Survey of Family Growth. 2006-2010 NSFG: Public use data files, codebooks, and documentation [user's guide]. Available at Http: // www. Cdc. Gov/nchs/nsfg/nsfg_2006_2010_puf. Htm. 2011.
32. Burstein HJ, Polyak K, Wong JS et al. Ductal carcinoma in situ of the breast. N Engl J Med 2004; 350: 1430-1441.
33. Partridge AH, Elmore JG, Saslow D et al. Challenges in ductal carcinoma in situ risk communication and decision-making: Report from an American Cancer Society and National Cancer Institute workshop. CA Cancer J Clin 2012; 62: 203-210.
34. Setiawan VW, Monroe KR, Wilkens LR et al. Breast cancer risk factors defined by estrogen and progesterone receptor status: The multiethnic cohort study. Am J Epidemiol 2009; 169: 1251-1259.
35. Grann VR, Troxel AB, ZojwallaNJ et al. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma. Cancer 2005; 103: 2241-2251.
36. Letourneau JM, Ebbel EE, Katz PP et al. Pretreatment fertility counseling and fertility preservation improve quality of life in reproductive age women with cancer. Cancer 2012; 118: 1710-1717.
37. Lee S, Heytens E, Moy F et al. Determinants of access to fertility preservation in women with breast cancer. Fertil Steril 2011; 95: 1932-1936.
38. Quinn GP, Vadaparampil ST, McGowan Lowrey K et al. State laws and regulations addressing thirdparty reimbursement for infertility treatment: Implications for cancer survivors. Fertil Steril 2011; 95: 72-78.
39. AMA adopts new policies on first day of voting at annual meeting [press release]. Available at http: //www. ama-assn. org/ama/pub/news/news/ 2013/2013-06-17-new-ama-policies-annual-meeting. page. Updated June 17, 2013. Accessed December 1, 2013.
40. Peate M, Meiser B, Cheah BC et al. Making hard choices easier: A prospective, multicentre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. Br J Cancer 2012; 106: 1053-1061.
41. Martin JA, Hamilton BE, Ventura SJ et al. Births: Final data for 2011. Nat Vital Stat Rep 2013; 62. Available at http: //www. cdc. gov/nchs/data/ nvsr/nvsr62/nvsr62_01. pdf. Accessed December 1, 2013.
42. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: A prospective controlled study. J Clin Oncol 2008; 26: 2630-2635.
43. Rippy EE, Karat IF, Kissin MW. Pregnancy after breast cancer: The importance of active counselling and planning. Breast 2009; 18: 345-350.
44. Azim HA Jr., Kroman N, Paesmans M et al. Prognostic impact of pregnancy after breast canceraccordingtoestrogenreceptorstatus: A multicenter retrospective study. J Clin Oncol 2013; 31: 73-79.
45. Kranick JA, Schaefer C, Rowell S et al. Is pregnancy after breast cancer safe? Breast J 2010; 16: 404-411.
46. Davies C, Pan H, Godwin J et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013; 381: 805-816.
47. Ruddy KJ, Gelber SI, Tamimi RM et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014; 32: 1151-1156.